Publication | Closed Access

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

MedicineMelanomaImmunologyPathologyResected MelanomaImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyNeoantigen Therapy Mrna-4157